lansoprazole has been researched along with Respiratory Tract Infections in 7 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 9.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 9.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 5.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes." | 5.17 | Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. ( Blake, KB; Gong, Y; Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wise, RA, 2013) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 5.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "Chronic obstructive pulmonary disease (COPD) is a common and progressive disease characterised by chronic cough, airflow limitation and recurrent exacerbations." | 2.66 | Proton pump inhibitors for chronic obstructive pulmonary disease. ( Imai, H; Kikuchi, S; Tajiri, T; Tani, Y; Watanabe, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, S | 1 |
| Imai, H | 1 |
| Tani, Y | 1 |
| Tajiri, T | 1 |
| Watanabe, N | 1 |
| Lima, JJ | 5 |
| Lang, JE | 3 |
| Mougey, EB | 2 |
| Blake, KB | 1 |
| Gong, Y | 1 |
| Holbrook, JT | 4 |
| Wise, RA | 3 |
| Teague, WG | 3 |
| Franciosi, JP | 1 |
| Wei, CY | 1 |
| Sukhovershin, RA | 1 |
| Ghebremariam, YT | 1 |
| Cooke, JP | 1 |
| Gold, BD | 1 |
| Blake, K | 1 |
| Brown, ED | 1 |
| Castro, M | 1 |
| Dozor, AJ | 1 |
| Mastronarde, JG | 1 |
| Sockrider, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013] | Phase 4 | 306 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24
| Intervention | mg/mL (Mean) |
|---|---|
| Lansoprazole Group | 2.6 |
| Placebo Group | 2.5 |
ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 0.86 |
| Placebo Group | 0.88 |
Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 5.8 |
| Placebo Group | 6.0 |
Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 1.1 |
| Placebo Group | 1.0 |
A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | Liters (Mean) |
|---|---|
| Lansoprazole Group | 2.2 |
| Placebo Group | 2.3 |
"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary
| Intervention | number of episodes of poor asthma contrl (Number) |
|---|---|
| Lansoprazole Group | 230 |
| Placebo Group | 184 |
1 review available for lansoprazole and Respiratory Tract Infections
| Article | Year |
|---|---|
Proton pump inhibitors for chronic obstructive pulmonary disease.
Topics: Aged; Disease Progression; Humans; Lansoprazole; Proton Pump Inhibitors; Pulmonary Disease, Chronic | 2020 |
3 trials available for lansoprazole and Respiratory Tract Infections
| Article | Year |
|---|---|
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Asthma; Bronchit | 2013 |
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Topics: Adolescent; Asthma; Child; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Gastroesophageal Reflu | 2015 |
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adolescent; Adrenal Cortex Horm | 2012 |
3 other studies available for lansoprazole and Respiratory Tract Infections
| Article | Year |
|---|---|
Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.
Topics: Cytochrome P-450 CYP2C19; Drug Interactions; Gastroesophageal Reflux; Genetic Variation; Humans; Lan | 2014 |
Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved?
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |